Registration - In-house Corporation

Viron Therapeutics Inc. / Kevin Sullivan, Vice President, Business Development

Registration Information

In-house Corporation name: Viron Therapeutics Inc.
Responsible Officer Name: Kevin Sullivan, Vice President, Business Development
Initial registration start date: 2008-07-16
Registration status: Inactive
Registration Number: 783339-220343

Associated Communications

Total Number of Communication Reports: 1

Monthly communication reports in the last 6 months: 0

Version 4 of 8 (2010-07-16 to 2010-12-16)

Registration versions:

Version 4 of 8 (2010-07-16 to 2010-12-16)

Lobbying Information

Subject Matters

Science and Technology

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Industrial Research Assistance Program (IRAP) funding is sought by Viron to advance our proprietary drug discovery program. Communications regarding the IRAP submission are between George Billjan (IRAP) and Dr. Steven Nazarian and Robert Browne from Viron Therapeutics.
Science and Technology funding is sought from Technology Partnerships Canada on an ongoing basis as per TPC Agreement NO. 720-492480. This funding supports advancement of Viron's proprietary drug discovery platform of immunomodulatory viral proteins.

Communication Techniques

Written communication
Oral communication

Government Institutions

Industrial Research Assistance Program (IRAP)
Technology Partnership Canada

In-house Corporation Details

Description of activities

Commercialization of therapeutic immunomodulatory viral proteins to combat inflammatory diseases. We interact with TPC and receive benefits as per awarded project #7720-492480. TPC falls within the jurisdiction of the Industry Minister.

Responsible officer name and position during the period of this registration

Kevin Sullivan, Vice President, Business Development

Government funding

End date of the last completed financial year: 2010-03-31

List of Government Funding
Government Institution	Funding Received in Last Financial Year	Funding Expected in Current Financial Year
Technology Partnerships Canada	$476,049.00	Yes

In-house Corporation Contact Information

Address:
700 Collip Circle, Suite 203
London, ON N6G 4X8
Canada

Telephone number: 519-858-5109
Fax number: 519-858-5103

Parent Company Information

Viron Therapeutics Inc. is not a subsidiary of any other parent companies.

Subsidiary Beneficiary Information

Viron Therapeutics Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

No lobbyists added

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Kevin Sullivan, Vice President, Business Development | No public offices held

Viron Therapeutics Inc.

The following names have been used on or after July 2, 2008

Name	From	To
Viron Therapeutics Inc.	2008-07-16	2012-09-02

Viron Therapeutics Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)

Date Modified:: 2026-03-23

Search and menus

Language selection

Registration - In-house Corporation

Viron Therapeutics Inc. / Kevin Sullivan, Vice President, Business Development

Registration Information

Associated Communications

Version 4 of 8 (2010-07-16 to 2010-12-16)

Version 4 of 8 (2010-07-16 to 2010-12-16)

Subject Matters

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties